Quotient Sciences: Translational Pharmaceutics platform
Quotient Sciences has announced the integration of drug substance into its Translational Pharmaceutics platform. The newly integrated service unites drug substance, drug product and clinical testing activities within a unified organization and under a single project manager.
Mark Egerton, Quotient Sciences CEO, said, “We remain the only outsourcing partner able to offer innovators the ability to manufacture, release, and dose under one organization. This approach is proven to shave 12-months off timelines and, by adding drug substance synthesis, the timeline from candidate selection to clinic can be further accelerated by two to four months.”